J Taylor1, R McMillan2, M Shephard3, J Setterfield4, R Ahmed5, M Carrozzo6, S Grando7, M Mignogna8, M Kuten-Shorrer9, T Musbah10, A Elia11, R McGowan12, A R Kerr13, M S Greenberg14, T Hodgson15, D Sirois16. 1. SPR Oral Medicine, University Dental Hospital of Manchester, Higher Cambridge Street, Manchester, UK. 2. Consultant and Honorary Clinical Teaching Fellow in Oral Medicine and Facial Pain, Eastman Dental Hospital, London, UK. 3. SPR Oral Medicine, Eastman Dental Hospital, London, UK. 4. Reader/Honorary Consultant in Dermatology in relation to Oral Disease, Department of Oral Medicine and St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. 5. Center For Blistering Diseases, Boston, Massachusetts, USA. 6. Professor of Oral Medicine, School of Dental Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne, UK. 7. Professor, Dermatology, School of Medicine, University of California, Irvine, CA 92697, USA. 8. Head of the Oral Medicine Complex Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences - Head and Neck Clinical Section, "Federico II" University, Naples, Italy. 9. Oral Medicine Resident, Harvard School of Dental Medicine, Boston, Massachusetts, USA. 10. Orofacial Pain Resident, Orofacial Pain Center, University of Kentucky College of Dentistry, Lexington, Kentucky, USA. 11. Oral Medicine Section, Department of Surgical Sciences, Lingotto Dental School, University of Turin, Turin, Italy. 12. Research Librarian, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University College of Dentistry, New York, New York, USA. 13. Clinical Professor, Department of Oral and Maxillofacial Pathology, Radiology and Medicine, New York University College of Dentistry, New York City, New York, USA. 14. Professor Emeritus, Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 15. Consultant in Oral Medicine/Honorary Senior Clinical Lecturer, Divisional Clinical Director, Eastman Dental Hospital, London, UK. 16. Associate Professor, Department of Oral and Maxillofacial Pathology, Radiology and Medicine, New York University College of Dentistry, New York City, New York, USA. Electronic address: ds62@nyu.edu.
Abstract
OBJECTIVE: To determine the efficacy and safety of interventions for mucous membrane pemphigoid (MMP). STUDY DESIGN: We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials and observational studies were included, with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. The primary outcome was lesion remission or healing; several relevant secondary outcomes were also included. RESULTS: In the final analysis, 1 RCT and 32 observational studies were included. The one included RCT with a high risk of bias in multiple domains found limited evidence that pentoxifylline, combined with corticosteroid and cyclophosphamide, was more effective than standard therapy (corticosteroid + cyclophosphamide alone) for ocular MMP. We summarize here the outcomes from 32 observational studies examining 242 patients across 19 unique treatments. Interventions that show promise include rituximab and intravenous immunoglobulin. CONCLUSIONS: This systematic review is the most recent since 2003-2009. There is still lack of high-quality research providing evidence-based MMP treatments.
OBJECTIVE: To determine the efficacy and safety of interventions for mucous membrane pemphigoid (MMP). STUDY DESIGN: We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials and observational studies were included, with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. The primary outcome was lesion remission or healing; several relevant secondary outcomes were also included. RESULTS: In the final analysis, 1 RCT and 32 observational studies were included. The one included RCT with a high risk of bias in multiple domains found limited evidence that pentoxifylline, combined with corticosteroid and cyclophosphamide, was more effective than standard therapy (corticosteroid + cyclophosphamide alone) for ocular MMP. We summarize here the outcomes from 32 observational studies examining 242 patients across 19 unique treatments. Interventions that show promise include rituximab and intravenous immunoglobulin. CONCLUSIONS: This systematic review is the most recent since 2003-2009. There is still lack of high-quality research providing evidence-based MMP treatments.
Authors: Jacqueline W Mays; Barbara P Carey; Rachael Posey; Luiz Alcino Gueiros; Katherine France; Jane Setterfield; Sook Bin Woo; Thomas P Sollecito; Donna Culton; Aimee S Payne; Martin S Greenberg; Scott De Rossi Journal: Oral Dis Date: 2019-06 Impact factor: 3.511